Unifying Framework for Acute Resolution, Malignancy and Autoimmunity

We wish to highlight 3 papers published last year which were all given a similar combination of treatment agents but demonstrated efficacy in 3 different tumor models; ie. (a) Ho et al administered GAP (anti-GITR, IFN-α, anti-PD1 with localized radiation) to treat 4T1 murine breast carcinoma with complete tumor eradication in 50% of treated mice, (b) Sallets et al treated murine B-Lymphoma with anti-GITR, localized intratumoral injection of STING agonist (whose downstream molecule is type I IFN) and anti-PD1, and achieved 50% complete tumor eradication, and (c) Schoenhals et al treated murine non-small cell lung carcinoma with anti-GITR, anti-PD1 and localized radiation (which they had previously demonstrated radiation mediated Type I IFN dependent mechanism was important for anti-PD1 treatment), and obtained 60% complete eradication.